Amnesia

Therapeutic Solutions International Completes FDA Requested Studies to Initiate JadiCell™ Chronic Traumatic Encephalopathy (CTE) Clinical Trial

Retrieved on: 
Monday, August 9, 2021
Aggression, COVID-19, Football, FDA, CEO, Dementia, B cell, Cell, Chronic traumatic encephalopathy, Muscle atrophy, Clinical trial, TSOI, Patient, Investigational New Drug, Athlete, Depression, Amnesia, Safety, IND, ELK, OTC Markets Group, CTE, Company, Pharmaceutical industry

The Company, which possesses the only filed Investigational New Drug (IND) application for treatment of chronic traumatic encephalopathy (CTE) was requested by the FDA to perform a series of experiments confirming several of the known properties of the JadiCell stem cells.

Key Points: 
  • The Company, which possesses the only filed Investigational New Drug (IND) application for treatment of chronic traumatic encephalopathy (CTE) was requested by the FDA to perform a series of experiments confirming several of the known properties of the JadiCell stem cells.
  • With the completion of these experiments, the Company is cautiously optimistic to be granted clearance to initiate this "first in class" new treatment approach for CTE.
  • We applaud the diligence and high level of scrutiny that the FDA has applied to our clinical trial and look forward to utilizing this novel approach to addressing this serious unmet medical need."
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

Odyssey Group International and Super Bowl MVPs Featured on “Banfield” Discussed Novel Concussion Treatment

Retrieved on: 
Friday, August 6, 2021
Odyssey, OTCQB, Company, Private Securities Litigation Reform Act, Concussion, COVID-19, Prevalence, Traffic barrier, Brain, OTC, Oxidative stress, CA, Neurosteroid, NFL, SAB, Technology, Inflammation, Awareness, FDA, Acquisition, Health, Anxiety, Drug development, Pathology, News, GLOBE, Interview, Amnesia, Pharmaceutical industry

IRVINE, CA, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC: ODYY ) (the "Company" or "Odyssey"), a health related company focused on developing unique, medical products including a treatment for concussion, recently appeared on Banfield with Ashleigh Banfield.

Key Points: 
  • IRVINE, CA, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC: ODYY ) (the "Company" or "Odyssey"), a health related company focused on developing unique, medical products including a treatment for concussion, recently appeared on Banfield with Ashleigh Banfield.
  • Odyssey Group International Appearance on Banfield Video:
    VP of Drug Development, Jake VanLandingham, along with members of its Sports Advisory Board (SAB), including NFL legends Brett Favre, Kurt Warner and Mark Rypien discussed the need for a treatment for concussion and provided an overview of the Companys drug candidate PRV-002, a novel neurosteroid being developed for the treatment of concussion.
  • The SAB supports Odysseys outreach efforts to enhance public awareness of concussion as well as the need for an FDA approved therapy.
  • Odyssey Group International, Inc. (OTCQB: ODYY ) is a technology and asset acquisition company with a focus in the area of life saving medical solutions.

Anesthetics Global Market Report 2021: COVID-19 Implications and Growth to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 6, 2021
Health, Pharmaceutical, Smart contract, GSK, Aspen, AstraZeneca, WHO, Safety, Irritation, Sensation, Injury, Pfizer, COVID-19, Patient, Saliva, Anesthetic, Hospira, Abbott Laboratories, Death, Patient safety, Anesthesia, Acquisition, Relaxation, Pain, IP, Intellectual property, Claris, Injection (medicine), Time, Amnesia, Accident, Fine chemical, Pharmaceutical industry, Medical device, Health insurance

The "Anesthetics Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anesthetics Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The anesthetics market consists of sales of drugs that cause a relaxing sensation to calm patients during surgery and remove the sensation of pain.
  • The anesthetics market is divided into general anesthetics, regional anesthetics, and local anesthetics.
  • Complying with these guidelines and getting regulatory approvals consumes a lot of time and negatively impacts the growth of the anesthetics market.

Sunrise Senior Living Appoints New Chief Operating Officer and Chief Financial Officer

Retrieved on: 
Thursday, August 5, 2021
Residential Building & Real Estate, Construction & Property, Seniors, Consumer, Senior living, Unibail-Rodamco-Westfield, Decision-making, Senior, Industry, TPG, Master of Business Administration, North America, University, Certified Public Accountant, Nursing, United, Limited liability partnership, PricewaterhouseCoopers, Growth, Patient, COVID-19, Finance, Quality of life, COO, Boston Consulting Group, Â, Travel + Leisure Co., Culture, Amnesia, Microsoft Dynamics 365 for Finance and Operations, Global Operations, Alzheimer's disease, Home, Marriott International, United Kingdom, Sunrise Senior Living, Chief financial officer, Management, Medicine

Sunrise Senior Living, a leading provider of senior living services, announced today the appointment of Nick Stengle as Chief Operating Officer (COO) and Tavinder (Tav) Hare as Chief Financial Officer (CFO).

Key Points: 
  • Sunrise Senior Living, a leading provider of senior living services, announced today the appointment of Nick Stengle as Chief Operating Officer (COO) and Tavinder (Tav) Hare as Chief Financial Officer (CFO).
  • Tav has a proven history of building strategic, high-performing teams that drive strong financial performance and enable expansion.
  • Mr. Stengle brings more than twenty years of executive experience in growth strategy development, global operations and leading major organizational initiatives to Sunrise.
  • Sunrise offers a full range of personalized senior living services, including independent living, assisted living, care for individuals with Alzheimer's and other forms of memory loss, as well as nursing and rehabilitative services.

Odyssey Group International Completes IND-enabling Studies, Submits Investigator’s Brochure for Phase 1 Clinical Trial

Retrieved on: 
Wednesday, August 4, 2021
Health sciences, Life sciences, Natural sciences, Pharmaceutical industry, Drug discovery, Clinical research, Food and Drug Administration, Clinical pharmacology, Clinical trial, Pharmacology, Drug development, ADME

Having successfully completed our IND-enabling studies and Investigational Brochure we have taken a large step closer to launching human clinical trials for a potential treatment for this unmet medical need, commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.

Key Points: 
  • Having successfully completed our IND-enabling studies and Investigational Brochure we have taken a large step closer to launching human clinical trials for a potential treatment for this unmet medical need, commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.
  • The IB includes the pre-clinical safety and efficacy data, the design for Phase 1 clinical trials and the informed consent to enroll subjects in the trial.
  • These study areas include the following: Safety Pharmacology, Toxicology, CMC (Chemistry Manufacturing and Control) activities, ADME (Absorption, Distribution, Metabolism and Excretion) and Genotoxicity.
  • said Michael Redmond, CEO of Odyssey Group International
    Odyssey Group International, Inc. (OTC: ODYY ) is a technology and asset acquisition company with a focus in the area of life saving medical solutions.